Amgen (AMGN) to Halt Discounts on Aranesp -NYTimes
More News related to AMGN
- Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
- XplosiveStocks.com: AAPL, MSFT, AMGN, XLNX, SPLS, MRVL Hot Stocks on the Move
- Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
- Beacon Equity Issues Technical Trade Alerts on Biotechnology Stocks: AMGN, CELG, GENZ, DNA, GILD, INCY
- Amgen (AMGN) volatility at 47
More News related to Corporate News
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
The New York Times is reporting that Amgen (Nasdaq: AMGN) will halt pricing discounts on several of its drugs: Aranesp, Neulasta and Neupogen. According to sources, critics are saying that Amgen's rebates on its key anemia drug, Aranesp, have caused overuse of the product "at a time of mounting concerns about the product’s safety."
Amgen continues to believe that its pricing policies have not contributed to an overuse of the drug, but, "Nevertheless, we believe these contracting changes, along with other modifications, help to clear up those possible misperceptions."
Amgen has announced that the change will take effect October 1, 2008.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
Corporate NewsInsiders' Blog
Stocks Mentioned
-0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
